RecruitingNot ApplicableNCT07246421

Glucagon Resistance in Patients With MASLD and T2DM

Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes

Sponsor

University of Aarhus

Enrollment

24 participants

Start Date

Jan 29, 2026

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes (T2DM)Metabolic Associated Fatty Liver Disease

Summary

The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD). The main questions it aims to answer are: 1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD? 2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose tissue? Researchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups. Participants will attend 2 short visits and 1 full-day visit, including: * Body scan (DXA) to check fat and bone composition * MRI to measure liver fat. * Blood tests. * Ultrasound to check liver stiffness and scarring. * Fat biopsies * 8-hour hormone (including glucagon) and tracer infusion * PET-CT scans

Eligibility

Min Age: 30 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study examines glucagon resistance — the reduced ability of the liver to respond to glucagon, a hormone that raises blood sugar — in people with metabolic fatty liver disease (MASLD) and type 2 diabetes. Understanding glucagon resistance could lead to better treatments for these conditions. **You may be eligible if...** - Your BMI is above 26 - You have been diagnosed with type 2 diabetes for at least 6 months - You have confirmed liver fat accumulation (steatosis above 5.6% on MRI) if you are in the fatty liver group **You may NOT be eligible if...** - You drink more than 10 units of alcohol per week - You smoke - You have had or currently have cancer - You donated blood within the last 3 months - You have a pacemaker or metal implants that would prevent MRI scanning Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGlugagon

Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers. \[11C\]palmitate PET during low and high dose glucagon.